Wendy Q. Qiu, MD, PhD
Associate Professor
Boston University School of Medicine
Dept of Psychiatry
General Psychiatry

MD, Beijing Medical University
PhD, Cornell University Medical College

Wendy Qiu is an Associate Professor in the Psychiatry Department, Pharmacology & Experimental Therapeutics Department, Alzheimer’s disease Center (ADC) at Boston University School of Medicine. She is also a faculty member in the Neuroscience Program at Boston University.

Dr. Qiu is both a physician and a scientist. She is a Board Certified Psychiatrist who was trained at Tufts Medical Center and at the Payne Whitney Clinic, New York Presbyterian Hospital, Cornell Medical Center. She currently spends 50% of her time caring for patients with dementia and other psychiatric illnesses, including late life depression, and seeing patients in the ADC for the clinical trials. Many of her patients seek care at BU because they are frustrated with their deteriorating cognitive function and their behavior or mood symptoms are causing tremendous burdens for their caregivers. Motivated by her desire to help patients with devastating diseases in geriatric psychiatry, especially dementia which frequently lacks diagnostic tools and effective therapies, Dr. Qiu devotes the other 50% of her time to researching the fundamental causational mechanisms of these diseases, and to translate her findings to seeking biomarkers for the diagnoses and treatment of psychiatric illnesses.

Research Interests:

-Identifying and studying the modifiable and non-modifiable risk factors and their mechanisms in Alzheimer’s disease (AD): We have an established homebound elderly population in the Boston area, and we are performing longitudinal evaluations of their cognition, psychiatric, and neurological conditions. Some of the homebound elderly have also taken part in brain imaging. Our study focuses on the relationship between late life depression, type 2 diabetes, and AD. Investigating the brain’s regulation of emotion, obesity/diabetes, and cognition in AD pathogenesis will help to develop novel treatments for the intervention and early treatment of AD.

-Identifying and studying the communication between peripheral biomarkers and brain abnormalities in aging and the prodromal stage of AD: We are targeting biomarkers that could lead to an early diagnosis of AD, especially Aß peptides and cytopkines found in blood and cerebral spinal fluid. We are also using neuro-imaging such as magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS), to study these biomarkers and brain composition.

-Investigating the Insulin Degrading Enzyme: Our study and others have identified that the insulin-degrading enzyme (IDE) plays a key role in the clearance of amyloid beta peptides (Aß), a major component in AD pathology. IDE also degrades insulin and amylin, and it might be a key component in type 2 diabetes. Our research goal is to further investigate whether defects of IDE activity and its regulation accelerates AD pathology in the elderly who suffer from type 2 diabetes.

Associate Professor
Boston University School of Medicine
Pharmacology & Experimental Therapeutics

2013 Boston Unviersity: J&J Clinical Innovation Award
2012 Boston University: Ignition Award
2003 New England Medical Center, Tufts University School of Medicine: CREFF Award
2002 New England Medical Center, Boston: Psychiatry Resident Award sponsored by Pfizer
2002 Tufts University School of Medicine: Resident Recognized for Excellence in Teaching
1999 Cornell Medical College, New York: Vincent du Vigneaud Prize for Excellent Research

Midcareer Investigator Award in Amylin, Cognition, and Alzheimer's Disease
09/01/2015 - 05/31/2018 (PI)
NIH/National Institute on Aging

Plasma Amylin Impact on Cognitive Function and Brain Morphology in the Framingham Heart Study
05/01/2015 - 01/31/2018 (PI)
NIH/National Institute on Aging

Setting up a Challenge Diagnostic Test for Alzheimer's Disease
12/01/2013 - 11/30/2017 (PI)
Alzheimer's Association

Amylin as a Diagnostic Test and Potential Treatment for Alzheimer's Disease
05/01/2014 - 02/28/2017 (PI)
NIH/National Institute on Aging

Removal of Amyloid-beta Peptides from the Brain in a Transgenic Mouse Model of Alzheimer's Disease
07/01/2014 - 06/30/2015 (PI)
We Biosciences, LLC NIH NIA

Plasma Amyloid-Beta Peptides, depression and Alzheimer's Disease
07/15/2009 - 06/30/2015 (PI)
NIH/National Institute on Aging

Yr Title Project-Sub Proj Pubs
2017 Plasma Amylin Impact on Cognitive Function and Brain Morphology in the Framingham Heart Study 5R01AG049899-03 2
2017 Plasma Amylin Impact on Cognitive Function and Brain Morphology in the Framingham Heart Study 3R01AG049899-03S1 2
2016 Midcareer Investigator Award in Amylin, Cognition, and Alzheimer's Disease 5K24AG050842-02 3
2016 Plasma Amylin Impact on Cognitive Function and Brain Morphology in the Framingham Heart Study 5R01AG049899-02 2
2016 Plasma Amylin Impact on Cognitive Function and Brain Morphology in the Framingham Heart Study 3R01AG049899-02S1 2
2015 Midcareer Investigator Award in Amylin, Cognition, and Alzheimer's Disease 1K24AG050842-01 3
2015 Plasma Amylin Impact on Cognitive Function and Brain Morphology in the Framingham Heart Study 1R01AG049899-01 2
2015 Amylin as a Diagnostic Test and Potential Treatment for Alzheimers Disease 5R21AG045757-02 1
2014 Amylin as a Diagnostic Test and Potential Treatment for Alzheimers Disease 1R21AG045757-01A1 1
2013 Plasma Amyloid-beta Peptides, Depression and Alzheimer's Disease in the Homebound 5R01AG031171-05 9
Showing 10 of 19 results. Show All Results
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Qiu WQ. Amylin and its G-protein-coupled receptor: A probable pathological process and drug target for Alzheimer''s disease. Neuroscience. 2017 Jul 25; 356:44-51. PMID: 28528968.
  2. Zhu H, Wang X, Wallack M, Li H, Carreras I, Dedeoglu A, Hur JY, Zheng H, Li H, Fine R, Mwamburi M, Sun X, Kowall N, Stern RA, Qiu WQ. Intraperitoneal injection of the pancreatic peptide amylin potently reduces behavioral impairment and brain amyloid pathology in murine models of Alzheimer''s disease. Mol Psychiatry. 2015 Feb; 20(2):252-62.View Related Profiles. PMID: 24614496; PMCID: PMC4161670; DOI: 10.1038/mp.2014.17;.
  3. Qiu WQ, Wallack M, Dean M, Liebson E, Mwamburi M, Zhu H. Association between amylin and amyloid-ß peptides in plasma in the context of apolipoprotein E4 allele. PLoS One. 2014; 9(2):e88063.View Related Profiles. PMID: 24520345; PMCID: PMC3919737; DOI: 10.1371/journal.pone.0088063;.
  4. Qiu WQ, Au R, Zhu H, Wallack M, Liebson E, Li H, Rosenzweig J, Mwamburi M, Stern RA. Positive association between plasma amylin and cognition in a homebound elderly population. J Alzheimers Dis. 2014; 42(2):555-63.View Related Profiles. PMID: 24898659; DOI: 10.3233/JAD-140210;.
  5. Vu LN, Dean MJ, Mwamburi M, Au R, Qiu WQ. Executive function and mortality in homebound elderly adults. J Am Geriatr Soc. 2013 Dec; 61(12):2128-34.View Related Profiles. PMID: 24479144; PMCID: PMC3919053.
  6. Qiu WW, Lai A, Mon T, Mwamburi M, Taylor W, Rosenzweig J, Kowall N, Stern R, Zhu H, Steffens DC. Angiotensin converting enzyme inhibitors and Alzheimer disease in the presence of the apolipoprotein E4 allele. Am J Geriatr Psychiatry. 2014 Feb; 22(2):177-85.View Related Profiles. PMID: 23567418; PMCID: PMC3873370; DOI: 10.1016/j.jagp.2012.08.017;.
  7. Brodoefel H, Ramachandran R, Pantol G, Bergethon P, Qiu WQ, Scott T, Rojas R, Horger M, Rosenberg I, Bhadelia RA. Association between linear measurements of corpus callosum and gait in the elderly. Eur Radiol. 2013 Aug; 23(8):2252-7. PMID: 23512195; DOI: 10.1007/s00330-013-2818-x;.
  8. Qiu WQ, Mwamburi M, Besser LM, Zhu H, Li H, Wallack M, Phillips L, Qiao L, Budson AE, Stern R, Kowall N. Angiotensin converting enzyme inhibitors and the reduced risk of Alzheimer''s disease in the absence of apolipoprotein E4 allele. J Alzheimers Dis. 2013; 37(2):421-8.View Related Profiles. PMID: 23948883; PMCID: PMC3972060; DOI: 10.3233/JAD-130716;.
  9. Ma XY, Qiu WQ, Smith CE, Parnell LD, Jiang ZY, Ordovas JM, Tucker KL, Lai CQ. Association between BDNF rs6265 and obesity in the Boston Puerto Rican Health Study. J Obes. 2012; 2012:102942. PMID: 23326649; PMCID: PMC3543800; DOI: 10.1155/2012/102942;.
  10. Zhu H, Bhadelia RA, Liu Z, Vu L, Li H, Scott T, Bergethon P, Mwamburi M, Rosenzweig JL, Rosenberg I, Qiu WQ. The association between small vessel infarcts and the activities of amyloid-ß peptide degrading proteases in apolipoprotein E4 allele carriers. Angiology. 2013 Nov; 64(8):614-20.View Related Profiles. PMID: 23076436; PMCID: PMC3788834; DOI: 10.1177/0003319712462125;.
Showing 10 of 44 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 44 publications over 20 distinct years, with a maximum of 6 publications in 2010

Contact for Mentoring:

85 E. Newton St Fuller Building
Boston MA 02118
Google Map

Qiu's Networks
Click the "See All" links for more information and interactive visualizations
Similar People
Same Department